|
US20010006629A1
(en)
*
|
1993-10-25 |
2001-07-05 |
Richard J. Gregory |
Recombinant adenoviral vector and methods of use
|
|
AU687117B2
(en)
*
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US6210939B1
(en)
|
1993-10-25 |
2001-04-03 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US20060275261A1
(en)
*
|
1993-10-25 |
2006-12-07 |
Canji, Inc. |
Adenoviral vectors having a protein IX deletion
|
|
JP2001518804A
(ja)
*
|
1997-03-21 |
2001-10-16 |
エンゾー セラピューティクス インコーポレイテッド |
ベクターおよびウイルスベクター、およびこれらを増殖するためのパッケージング細胞株
|
|
US8703480B1
(en)
|
1997-03-21 |
2014-04-22 |
Enzo Therapeutics, Inc. |
Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
|
|
AU6962698A
(en)
|
1997-04-11 |
1998-11-11 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Transgenomic viruses and the use thereof
|
|
WO1999044423A1
(en)
*
|
1998-03-03 |
1999-09-10 |
The Uab Research Foundation |
Amplification of gene transfer and gene therapy by controlled replication
|
|
US20060183228A1
(en)
*
|
1998-03-24 |
2006-08-17 |
Enzo Therapeutics, Inc. |
Viral vectors with surface or envelope components
|
|
FR2778670B1
(fr)
|
1998-05-18 |
2002-12-13 |
Rhone Poulenc Rorer Sa |
Methodes et compositions pour la production de particules virales
|
|
AU6149099A
(en)
*
|
1998-09-22 |
2000-04-10 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Replication deficient retroviral vector system and methods of using
|
|
US7052904B2
(en)
|
2000-01-31 |
2006-05-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Hybrid adeno-retroviral vector for the transfection of cells
|
|
EP1287153B1
(en)
|
2000-05-31 |
2009-09-30 |
Human Gene Therapy Research Institute |
Methods and compositions for efficient gene transfer using transcomplementary vectors
|
|
US7226779B2
(en)
|
2001-01-30 |
2007-06-05 |
The United States Of America As Represented By The Department Of Health And Human Services |
Hybrid adenoviral vector
|
|
US7271150B2
(en)
|
2001-05-14 |
2007-09-18 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified growth hormone
|
|
EP1442125A4
(en)
*
|
2001-10-04 |
2004-12-08 |
Carlos Estuard Aguilar-Cordova |
CHIMERAL VIRUS VECTORS FOR GENE THERAPY
|
|
US20070037284A1
(en)
*
|
2003-06-04 |
2007-02-15 |
Enzo Therapeutics, Inc. |
Vectors for expressing exogenous gene or exogenous nucleic acid sequences
|
|
ES2292271B1
(es)
*
|
2004-05-20 |
2009-02-16 |
Proyecto De Biomedicina Cima, S.L. |
Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
|
|
WO2011123518A1
(en)
|
2010-03-31 |
2011-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
|
|
WO2021108500A1
(en)
|
2019-11-26 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
T cell receptors targeting mutations in rna splicing factors
|
|
US20230348557A1
(en)
|
2020-02-06 |
2023-11-02 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
T cell receptors Targeting Defective DNA Repair Proteins
|
|
US10822379B1
(en)
|
2020-03-12 |
2020-11-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Molecules that bind to SARS-CoV-2
|